Show simple item record

dc.contributor.authorRoblin, P M
dc.contributor.authorMontalban, G
dc.contributor.authorHammerschlag, M R
dc.date.accessioned2023-06-30T16:19:08Z
dc.date.available2023-06-30T16:19:08Z
dc.date.issued1994-07
dc.identifier.citationRoblin PM, Montalban G, Hammerschlag MR. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother. 1994 Jul;38(7):1588-9. doi: 10.1128/AAC.38.7.1588. PMID: 7979292; PMCID: PMC284597.en_US
dc.identifier.issn0066-4804
dc.identifier.pmid7979292
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10337
dc.description.abstractWe tested in vitro 49 isolates of Chlamydia pneumoniae obtained from 35 children with community-acquired pneumonia against clarithromycin and erythromycin. The children were part of a treatment study comparing the two drugs. Clarithromycin was 2- to 10-fold more active than erythromycin, with a MIC for 90% of strains tested and minimal chlamydiacidal concentration for 90% of strains tested of 0.031 microgram/ml compared with 0.125 microgram/ml for erythromycin. Eight of these children, two of whom were treated with erythromycin and six of whom received clarithromycin, remained culture positive after treatment. We were able to test 21 isolates from these children. All were susceptible to both drugs, and the MICs did not change after therapy.
dc.language.isoenen_US
dc.relation.urlhttps://journals.asm.org/doi/epdf/10.1128/aac.38.7.1588en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleSusceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAntimicrobial agents and chemotherapyen_US
dc.source.volume38
dc.source.issue7
dc.source.beginpage1588
dc.source.endpage9
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-06-30T16:19:09Z
html.description.abstractWe tested in vitro 49 isolates of Chlamydia pneumoniae obtained from 35 children with community-acquired pneumonia against clarithromycin and erythromycin. The children were part of a treatment study comparing the two drugs. Clarithromycin was 2- to 10-fold more active than erythromycin, with a MIC for 90% of strains tested and minimal chlamydiacidal concentration for 90% of strains tested of 0.031 microgram/ml compared with 0.125 microgram/ml for erythromycin. Eight of these children, two of whom were treated with erythromycin and six of whom received clarithromycin, remained culture positive after treatment. We were able to test 21 isolates from these children. All were susceptible to both drugs, and the MICs did not change after therapy.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAntimicrobial agents and chemotherapy
dc.identifier.issue7en_US


Files in this item

Thumbnail
Name:
aac.38.7.1588.pdf
Size:
395.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International